Audit: QRS - Banaba Leaf for Health & Longevity

Audit conducted on 17/08/2026 04:44 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses, time-to-effect values, gate items, tiered benefits/risks, biomarker rows and cadence trace to ER lines 264–284, 300–315, 340, 362–380.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER empty-state or hedged phrasing was replaced; the At-A-Glance mirrors the Conclusion’s “Effects are small next to established treatments”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and breastfeeding at any stage” remains under Contraindications, matching the ER’s avoid list.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER avoid list, Key Interactions from the interaction bullets, Risks from Potential Risks & Side Effects; no modifying factor was promoted.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names (GlucoHelp, Soft Gel Technologies) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	Trial references are generic (“the dose-ranging trial”, “the crossover trial”) and match the ER’s own descriptions.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-first register throughout, matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and doses paired with plain-language explanation.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as observed trial practice, not instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; protocol cells describe what was used in trials.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, or “should” language anywhere.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in any populated span.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Drug-class names in the gates are load-bearing decision content; all other prose is plain.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are single terse phrases; subs are one sentence.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges (fasting glucose 75–86 mg/dL, HOMA-IR below 1.0) rather than conventional cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Daily capillary/continuous glucose for two weeks and a nine-marker panel assume a committed reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring cadence and qualitative tracking exceed general-population expectations.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance flags that effects are small next to established treatments, matching the ER’s weighting.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Blood sugar” mirrors the ER’s own Conclusion and benefit heading wording; no consumer-grade substitutions elsewhere.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings byte-identical to the template (lines 446, 492, 539, 607, 630, 773, 567, 580, 634–636).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 37 template variables present; marker_#_* expanded to 1–9 and qualitative_item_# to 1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows changes confined to checklist-addressed spans and the metadata block.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section drawn on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standardized 1% corosolic acid extract”, “Whole-leaf water extract”, “Isolated corosolic acid” are the ER’s bold labels verbatim (ER lines 302–304).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names and protocol labels match the ER exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points in the file; the ER’s 🟩/🟥/🟨 and ⚠️ markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to its shortest faithful form — gate items are bare phrases, tier lines are semicolon-joined headings, subs are single sentences.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” line 3, closing “—” line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed on the page except the derived subline date and model name.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: banaba_leaf_2026-0825-0225_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-0432.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the actual filename banaba_leaf_2026-0825-0225_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: all nine keys clean; git_issue: 5246 and git_user: evipedia-2 unquoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Banaba Leaf for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Banaba Leaf for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/17/2026, matching qrs_creation_date 2026-0817-0432.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; no AKA line despite the ER carrying eight alternate names.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER Conclusion paragraphs 1–2 (lines 396–398) into four sentences.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Traditional tea plant / concentrated extract (line 396), unsettled active compound (line 396), post-meal and fasting glucose plus lipids/insulin/BP (line 398), small vs established treatments (line 398).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “blood sugar”, “blood fat”, “active plant compounds”; no acronyms, no “corosolic acid”, no “metabolic syndrome”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only the generic “Short trials show”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers appear in the span.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from “Populations who should avoid Banaba Leaf”, ER lines 277–284.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-list entries present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements, lines 570–575.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	”, given the acute kidney injury case report”, “— no human safety data exist at any dose”, “— no trial has enrolled this group”, “, because of unpredictable perioperative glucose control” and “, where clearance of a concentrated botanical is unstudied” all stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“stage 3b or worse (eGFR below 45 mL/min/1.73 m²)”, “at any stage”, “under 18”, “Within two weeks”, “Child-Pugh Class B or C” all retained; only the eGFR definitional gloss was trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s avoid list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is populated accordingly.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the ten interaction bullets, ER lines 266–275.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten interaction bullets present; no overlap with the six contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Ten <li> elements, lines 583–597.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “— caution:”/”— monitor:” tail and its mitigation sentence removed; only the agent or exposure name remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All example drug lists retained verbatim; only the definitional gloss “drugs prompting the pancreas to release insulin:” was trimmed from the secretagogue parenthesis.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and the section is populated accordingly.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from Therapeutic Protocol, ER lines 302–304.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three dosing regimens — standardized 1% extract, whole-leaf water extract, isolated corosolic acid — are the ER’s only directly actionable dose bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	32–48 mg/day, 500 mg twice daily and 10 mg pre-meal with their supporting subs all match ER lines 302–304.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Post-meal glucose, fasting glucose and insulin/lipids/blood pressure — the three windows named in ER line 340.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered post-meal glucose rise (Medium tier, first benefit) → fasting glucose (Medium) → insulin/lipids/blood pressure (Medium then Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	60–90 minutes, 2 weeks and 12 weeks with subs traceable to ER lines 340, 154–176 and 308.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 340), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine benefit headings from ER lines 144–196 are represented.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present, lines 541–560.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of the ER’s benefit headings; all Magnitude and Basis prose dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High-tier benefit; line 541 sets benefits_high to style="display: none" with empty content.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six risk headings from ER lines 214–250 are represented.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present, lines 609–624.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of the ER’s risk headings; no Magnitude or Basis prose carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High-tier risk; line 609 sets risks_high to style="display: none" with empty content.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from Monitoring Protocol & Defining Success, ER lines 356–372.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows present as marker_1–marker_9 with targets and rationales verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 763–767 condense ER line 360 (daily for two weeks, four weeks, 12 weeks, every six months).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from “Qualitative markers worth tracking alongside the labs”, ER lines 374–380.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present as qualitative_item_1–5, verbatim.

Issues 17/08/2026 04:44

Pass rate 100.00%. No issues found.

Issues 17/08/2026 04:38

1. 11.4 — Time-to-effect subs restate label and value: time_3_sub at line 526 reads “Insulin, lipid and blood pressure changes took 12 weeks.”, which reproduces time_3_label (“Insulin, lipids, blood pressure”) and time_3_value (“12 weeks”) without adding content; time_1_sub at line 504 similarly restates its label and value.

Fixes 17/08/2026 04:38

1. 11.4 — Time-to-effect subs restate label and value: Rewrote time_1_sub from “Post-meal glucose effects appear after the first dose.” to “Present from the first dose, as the gut enzyme inhibition acts on carbohydrate in the meal itself.”, and time_3_sub from “Insulin, lipid and blood pressure changes took 12 weeks.” to “All three tracked together in the 12-week metabolic syndrome trial.”, so both cells add ER-derived content beyond their label and value.